Skip to main navigation Skip to search Skip to main content

Low rates of cardiotoxicity during HER2-directed antibody therapy for breast cancer across a large, Western US hospital system

Research output: Other contribution

Original languageUndefined/Unknown
StatePublished - Nov 7 2025

Publication series

NameArticles, Abstracts, and Reports

Cite this